MX2011009669A - Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes. - Google Patents
Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.Info
- Publication number
- MX2011009669A MX2011009669A MX2011009669A MX2011009669A MX2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A
- Authority
- MX
- Mexico
- Prior art keywords
- influence
- excipients
- pharmaceutical composition
- controlled release
- coating
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 6
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 title abstract 2
- 239000011248 coating agent Substances 0.000 title 1
- 238000000576 coating method Methods 0.000 title 1
- 229920002959 polymer blend Polymers 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000011247 coating layer Substances 0.000 abstract 2
- 229940075534 amino methacrylate copolymer Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 239000004014 plasticizer Substances 0.000 abstract 1
- 229920006163 vinyl copolymer Polymers 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención trata sobre una composición farmacéutica de liberación controlada, que consta de un núcleo, que consta de un ingrediente farmacéutico activo, donde el núcleo está revestido por una capa de revestimiento que proporciona resistencia y que tiene el efecto de proporcionar el perfil de liberación del ingrediente farmacéutico activo para que sea resistente a la influencia del etanol, en donde la capa de revestimiento que proporciona resistencia al etanol consta de al menos 70% por peso de una mezcla de una porción polimérica a) y una porción de excipientes b), donde la porción polimérica a) está presente en una cantidad de al menos 3.0% por peso calculada en el peso del núcleo y donde la porción polimérica a) consta de una mezcla de polímeros a1) y a2) con a1) 60 a 99% por peso, con base en el peso en seco de la mezcla polimérica, de un polímero de vinilo o un copolímero de vinilo esencialmente neutral insoluble en agua, y a2) 1 a 40% por peso, con base en el peso seco de la mezcla polimérica, de un copolímero amino (met) acrilato, que es soluble en un medio acuoso amortiguado hasta de ph 4.0 e insoluble al menos por encima de ph 5.0 y la porción de excipientes b) que consta de los excipientes b1) 60 a 250% por peso de un lubricante inerte no poroso b2) 0.1 a 25% por peso de un emulsionante y además o de manera alternativa a b2) b3) 0.1 a 30% por peso de un plastificante y de forma opcional b4) 1 - 35% por peso de un compuesto celulósico. donde los excipientes de la porción de excipientes b) se calculan en peso en seco de la porción polimérica a).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2009/053177 WO2010105673A1 (en) | 2009-03-18 | 2009-03-18 | Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011009669A true MX2011009669A (es) | 2011-12-14 |
Family
ID=40752823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011009669A MX2011009669A (es) | 2009-03-18 | 2009-03-18 | Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20110311631A1 (es) |
EP (1) | EP2408437A1 (es) |
JP (1) | JP5619131B2 (es) |
KR (1) | KR20120003436A (es) |
CN (1) | CN102365083A (es) |
BR (1) | BRPI0924427A2 (es) |
CA (1) | CA2755814A1 (es) |
IL (1) | IL214612A0 (es) |
MX (1) | MX2011009669A (es) |
WO (1) | WO2010105673A1 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011112709A1 (en) * | 2010-03-09 | 2011-09-15 | Elan Pharma International Limited | Alcohol resistant enteric pharmaceutical compositions |
SG184523A1 (en) | 2010-05-10 | 2012-11-29 | Euro Celtique Sa | Pharmaceutical compositions comprising hydromorphone and naloxone |
WO2011141490A1 (en) | 2010-05-10 | 2011-11-17 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
AU2011252040C1 (en) | 2010-05-10 | 2015-04-02 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
RU2606588C2 (ru) * | 2011-06-17 | 2017-01-10 | Эвоник Рем ГмбХ | Композиция покрытия, подходящая для фармацевтических или нутрицевтических дозированных форм |
KR101799625B1 (ko) | 2011-06-17 | 2017-11-20 | 에보니크 룀 게엠베하 | 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물 |
JP6099638B2 (ja) | 2011-06-17 | 2017-03-22 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングEvonik Roehm GmbH | エタノールの影響に耐性のある胃液抵抗性の医薬又は栄養補助組成物 |
FR2986431B1 (fr) * | 2012-02-03 | 2017-03-17 | Servier Lab | Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques |
CA2877774C (en) | 2012-07-12 | 2017-07-18 | Mallinckrodt Llc | Extended release, abuse deterrent pharmaceutical compositions |
US10835495B2 (en) | 2012-11-14 | 2020-11-17 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same |
US20140141075A1 (en) | 2012-11-21 | 2014-05-22 | Warner Chilcott Company, Llc | 5-aminosalicylic acid capsule formulation |
EP2945994B1 (en) | 2013-01-18 | 2018-07-11 | Basf Se | Acrylic dispersion-based coating compositions |
JP6150564B2 (ja) * | 2013-03-08 | 2017-06-21 | 杏林製薬株式会社 | 口腔内速崩壊性錠剤 |
US10064826B2 (en) | 2013-03-15 | 2018-09-04 | Navinta, Llc | Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process |
WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
SG11201602884WA (en) | 2013-11-13 | 2016-05-30 | Euro Celtique Sa | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
AU2015290098B2 (en) | 2014-07-17 | 2018-11-01 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
JP2017531026A (ja) | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 徐放性乱用抑止性液体充填剤形 |
US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US10722471B2 (en) * | 2016-02-03 | 2020-07-28 | Novartis Ag | Galenic formulations of organic compounds |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
CN106727435B (zh) * | 2016-12-26 | 2020-06-02 | 浙江工业大学 | 一种美托洛尔缓释胶囊及其制备方法 |
US11554114B2 (en) * | 2017-03-31 | 2023-01-17 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredients |
US20200289423A1 (en) | 2017-09-14 | 2020-09-17 | Evonik Operations Gmbh | Polymer and dosage form with sustained release properties and resistance against the influence of ethanol |
EP3727384A4 (en) | 2017-12-20 | 2021-11-03 | Purdue Pharma L.P. | ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES |
KR20200130369A (ko) | 2018-03-09 | 2020-11-18 | 에보니크 오퍼레이션즈 게엠베하 | 에탄올의 영향에 대한 내성을 갖는 중합체 혼합물 |
KR102138253B1 (ko) * | 2018-08-17 | 2020-07-29 | 한국유나이티드제약 주식회사 | 실로스타졸 서방성 제제 |
KR20210094513A (ko) * | 2018-11-19 | 2021-07-29 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 알코올-내성 약물 제형 |
TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
CN112294777B (zh) * | 2020-11-04 | 2022-07-05 | 南京康川济医药科技有限公司 | 一种盐酸伊伐布雷定缓释制剂及其制备方法和应用 |
WO2023280962A1 (en) * | 2021-07-09 | 2023-01-12 | Evonik Operations Gmbh | Composition comprising a (meth)acrylate copolymer, an alkali or ammonium salt of a saturated aliphatic monocarboxylic acid and specific glidants |
CN113925838B (zh) * | 2021-11-11 | 2022-11-11 | 乐普制药科技有限公司 | 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法 |
WO2023224097A1 (ja) * | 2022-05-18 | 2023-11-23 | 東和薬品株式会社 | 膜形成用組成物、膜状組成物及びその利用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2655266B1 (fr) * | 1989-12-05 | 1992-04-03 | Smith Kline French Lab | Compositions pharmaceutiques a base de cimetidine. |
US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
AU5775398A (en) * | 1996-12-17 | 1998-07-15 | Poli Industria Chimica S.P.A. | Site-specific controlled release dosage formulation for mesalamine |
US6524620B2 (en) * | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
DE19918435A1 (de) * | 1998-07-23 | 2000-01-27 | Roehm Gmbh | Überzugs- und Bindemittel für orale oder dermale Arzneiformen |
US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
DE10208335A1 (de) * | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Arzneiform und Verfahren zu ihrer Herstellung |
MXPA05002623A (es) * | 2002-09-09 | 2005-05-05 | Biovail Lab Inc | Formulaciones cronoterapeuticas de diltiazem y la administracion de las mismas. |
DE10250543A1 (de) * | 2002-10-29 | 2004-05-19 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform |
US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
RU2372893C2 (ru) * | 2003-10-31 | 2009-11-20 | Хексал Аг | Содержащий фармацевтический агент состав с покрытием |
AU2006208627B8 (en) * | 2005-01-28 | 2009-08-13 | Mundipharma Pty Limited | Alcohol resistant dosage forms |
DE102005024614A1 (de) * | 2005-05-25 | 2006-11-30 | Röhm Gmbh | Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug |
RU2433817C2 (ru) * | 2006-01-21 | 2011-11-20 | Эбботт Гмбх Унд Ко.Кг | Лекарственная форма и способ для доставки вызывающих зависимость лекарственных веществ |
DE102006051020A1 (de) * | 2006-10-26 | 2008-04-30 | Evonik Röhm Gmbh | Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung |
PL2187873T3 (pl) * | 2007-08-13 | 2019-01-31 | Abuse Deterrent Pharmaceutical Llc | Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania |
PL2187876T3 (pl) * | 2007-09-21 | 2013-01-31 | Evonik Roehm Gmbh | Farmaceutyczna kompozycja opioidowa o zależnym od pH kontrolowanym uwalnianiu z odpornością przed wpływem etanolu |
-
2009
- 2009-03-18 BR BRPI0924427A patent/BRPI0924427A2/pt not_active IP Right Cessation
- 2009-03-18 EP EP09779170A patent/EP2408437A1/en not_active Withdrawn
- 2009-03-18 JP JP2012500079A patent/JP5619131B2/ja not_active Expired - Fee Related
- 2009-03-18 KR KR1020117021575A patent/KR20120003436A/ko not_active Ceased
- 2009-03-18 MX MX2011009669A patent/MX2011009669A/es active IP Right Grant
- 2009-03-18 WO PCT/EP2009/053177 patent/WO2010105673A1/en active Application Filing
- 2009-03-18 CA CA2755814A patent/CA2755814A1/en not_active Abandoned
- 2009-03-18 US US13/203,760 patent/US20110311631A1/en not_active Abandoned
- 2009-03-18 CN CN2009801581095A patent/CN102365083A/zh active Pending
-
2011
- 2011-08-11 IL IL214612A patent/IL214612A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN102365083A (zh) | 2012-02-29 |
US20110311631A1 (en) | 2011-12-22 |
IL214612A0 (en) | 2011-09-27 |
BRPI0924427A2 (pt) | 2016-01-26 |
KR20120003436A (ko) | 2012-01-10 |
JP2012520832A (ja) | 2012-09-10 |
WO2010105673A1 (en) | 2010-09-23 |
JP5619131B2 (ja) | 2014-11-05 |
CA2755814A1 (en) | 2010-09-23 |
EP2408437A1 (en) | 2012-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011009669A (es) | Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes. | |
MX2011009667A (es) | Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante el uso de un revestimiento compuesto de polímeros de vinilo neutrales y excipientes. | |
MX347227B (es) | Composicion farmaceutica o nutraceutica con liberacion sostenida caracteristica y con resistencia contra la influencia del etanol. | |
WO2010064126A3 (en) | Controlled release dosage forms | |
MX355662B (es) | Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influencia de etanol. | |
WO2012085043A3 (en) | Rapidly disintegrating, solid coated dosage form | |
BRPI0720626A2 (pt) | Composição formadora de película, nanopartículas modificadas, revestimento resistente a risco, usos de um copolímero segmentado, e de nanopartículas modificadas | |
MX2016010437A (es) | Composicion farmaceutica o nutraceutica con caracteristica de liberacion sostenida y con resistencia contra la influencia del etanol. | |
WO2010005726A3 (en) | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same | |
NZ600123A (en) | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture | |
WO2011106416A3 (en) | Abuse-resistant formulations | |
MX362838B (es) | Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente. | |
WO2012034079A3 (en) | Macrolide dosage forms | |
IL203901A (en) | Opioid-controlled controlled-release drug - with high alcohol resistance, process, preparation and use | |
MX376383B (es) | Composicion farmaceutica o nutraceutica con resistencia contra la influencia del etanol | |
BR112014002837A2 (pt) | dispersão aquosa com baixo teor de formaldeído de um copolímero de vinil éster/etileno preparado por meio de copolimerização de emulsão de uma mistura de monômero; composição de adesivo; produto de cigarro; e uso da composição de adesivo | |
WO2010106314A3 (en) | Formulation comprising avermectin particles coated with a photo - protecting agent | |
WO2011053003A3 (en) | Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer | |
EP3856806A4 (en) | AQUEOUS POLYMER DISPERSION AND AQUEOUS COATING COMPOSITION THEREOF | |
WO2009121970A3 (de) | Schichtmaterial | |
WO2010005732A3 (en) | Composition and method of preparation of release systems for constant (zero-order) release of active agents | |
WO2014106116A3 (en) | Therapeutic compositions comprising antibodies | |
BR112013027484A8 (pt) | Composição farmacêutica ou nutracêutica com resistência gástrica, e uso de um polímero de (met)acrilato | |
WO2013012666A3 (en) | Compounds, methods of making, and methods of use | |
BR112012022363A2 (pt) | forma de dosagem com liberação modificada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |